Lakewood-Amedex Biotherapeutics Inc.
Tracked across 2 events · 14 articles · First seen Jun 26, 2026 · Last active Sep 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Lakewood-Amedex Biotherapeutics Inc. announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial of its lead product candidate…
Impact: The company is the sole actor in this event, securing IRB approvals and site readiness for the Phase 2a Nu-3 trial in infected diabetic foot ulcers. The milestone advances its lead Bisphosphocin candidate and modestly improves its clinical and financing narrative.
Sep 18, 2026 · 8 articles
Business
Impact: Lakewood-Amedex Biotherapeutics Inc. was one of the presenting companies at the Life Sciences Virtual Investor Forum.
Jun 26, 2026 · 6 articles
80
Lakewood-Amedex Biotherapeutics Inc. obtained IRB approvalsLakewood-Amedex Nu-3 Phase...
ERGEN INTELLIGENCE
Track Lakewood-Amedex Biotherapeutics Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard